Form 4: Jazz Pharmaceuticals EVP Philip L. Johnson Sells Shares to Cover Tax Obligations
SEC Form 4
Philip L. Johnson, EVP & Chief Financial Officer of Jazz Pharmaceuticals plc, sold 1,149 ordinary shares on March 5, 2025, to satisfy tax obligations arising from vesting restricted stock units.
Summary
- Philip L. Johnson, the EVP & Chief Financial Officer of Jazz Pharmaceuticals plc, reported a transaction involving the sale of ordinary shares.
- On March 5, 2025, Johnson sold 1,149 shares at a price of $138.95 per share.
- This transaction was executed to cover tax obligations related to the vesting of previously granted restricted stock units.
- Following the transaction, Johnson directly owns 50,060 ordinary shares of Jazz Pharmaceuticals plc.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing related to an executive's stock sale for tax purposes. It doesn't convey any particularly positive or negative sentiment regarding the company's performance or outlook.
Industry Context
Executive stock sales are a common occurrence, often related to compensation and tax planning. The sale itself is unlikely to have a significant impact on the company's overall performance or stock price, but it provides insight into executive financial decisions.
Stakeholder Impact
- The transaction has a minimal impact on shareholders, as it is a routine sale of shares by an executive for tax purposes.
Key Dates
| Date | Description |
|---|---|
| 03/05/2025 | Date of transaction: Sale of 1,149 ordinary shares. |
| 03/07/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.